Dr. Michael Mithoefer has been flown to New York City and is being interviewed today for the upcoming prime-time Ecstasy documentary being created by Peter Jennings’ documentary team. We’re …
We’re still waiting on DEA to issue Dr. Mithoefer his Schedule I license. DEA claims it is waiting to hear from FDA regarding a requested consultation about Dr. Mithoefer’s qualifications to …
MAPS submits a Freedom of Information Act (FOIA) request to FDA seeking copies of all correspondence between FDA and either the DEA, the Office of National Drug Control Policy, or the Partnership for a …
Dr. Mithoefer learned today that on December 11, 2003, the South Carolina DEA office submitted its recommendation to DEA headquarters that it give Dr. Mithoefer his Schedule I license for the MDMA/PTSD …
Research on Ecstasy Is Clouded by Errors – The New York Times, by Donald G. McNeil Jr. Rick Doblin, President of MAPS, published these comments on the NYT article. The Drug Policy Alliance have issued …
The politics of Research by Harry Shapiro, is published in the Nov/Dec issue of the British magazine, Druglink. This article reports that Ricaurte’s mislabeling error “came to light when a …
The British newspaper The Guardian published a positive article today about MAPS’ progress towards final approval of our MDMA/PTSD study. Later today, BBC Scotland will interview me about the MDMA/PTSD …
MAPS’ MDMA/PTSD research team met in Charleston, South Carolina to review the forms and procedures that will be used to conduct the study. The meeting went extremely well. Amy and Todd, the clinical …
Dr. Mithoefer receives his Schedule I research registration (R1) from South Carolina’s Department of Health and Environmental Control (DHEC). Dr. Mithoefer is still waiting on his DEA Schedule I …
RTI denies it made mistake that torpedoed results of a $1.3M study. Triangle Business Journal, by Leo John.
Several DEA agents inspected Dr. Mithoefer’s facility today as part of DEA’s review of his application for a Schedule I license to handle the 3.5 grams of MDMA needed for the entire study. …
Though MAPS’ long series of interactions with multiple IRBs was often frustrating, several improvements have been incorporated into the protocol design as a result of recommendations/requirements …
